Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURETHAL Mites Dose Finding in HDM Allergic Rhinitis
NCT01438463Phase 2Completed
- Sponsor
- HAL Allergy Group
- Start
- Sep 2011
- Primary completion
- May 2013
- Modality
- Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 5
01
Overview
A Phase 2 trial of Purethal in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by HAL Allergy Group. Started Sep 2011; status: completed.
02
Drugs
Purethal
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01438463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01438463.